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Crotamine induces browning of 
adipose tissue and increases energy 
expenditure in mice
Marcelo P. Marinovic1, Joana D. Campeiro1, Sunamita C. Lima1, Andrea L. Rocha2, Marcela B. 
Nering1, Eduardo B. Oliveira3, Marcelo A. Mori2,4 & Mirian A. F. Hayashi1
Crotamine, originally isolated from rattlesnake venom, has been extensively studied due to its 
pleiotropic biological properties, and special attention has been paid to its antitumor activity. However, 
long-term treatment with crotamine was accompanied by a reduction in animal body weight gain and 
by increases in glucose tolerance. As cancer is commonly associated with cachexia, to preclude the 
possible cancer cachexia-like effect of crotamine, herein this polypeptide was administered in healthy 
wild-type C57/BL6 mice by the oral route daily, for 21 days. Reduced body weight gain, in addition to 
decreased white adipose tissue (WAT) and increased brown adipose tissue (BAT) mass were observed 
in healthy animals in the absence of tumor. In addition, we observed improved glucose tolerance and 
increased insulin sensitivity, accompanied by a reduction of plasma lipid levels and decreased levels of 
biomarkers of liver damage and kidney disfunctions. Importantly, long-term treatment with crotamine 
increased the basal metabolic rate in vivo, which was consistent with the increased expression of 
thermogenic markers in BAT and WAT. Interestingly, cultured brown adipocyte cells induced to 
differentiation in the presence of crotamine also showed increases in some of these markers and in lipid 
droplets number and size, indicating increased brown adipocyte maturation.
Metabolism is regulated by a balance between energy expenditure and food intake1. In mammals, this balance 
is orchestrated by white adipose tissue (WAT) and brown adipose tissue (BAT)2,3. WAT is a specialized tissue 
for energy storage, in which triglycerides accumulate in large unilocular lipid droplets within adipocytes. Once 
needed, the white adipocytes can mobilize energy by hydrolyzing the triglycerides with the subsequent release 
of free fatty acids (FFAs), which are the key substrates for energy production in vertebrates during fasting4. In 
addition to its function in energy storage, WAT depots can also turn into energy dissipating tissues under cold 
exposure, adrenergic stimulation, and exercise, among others conditions5. This occurs mainly due to the recruit-
ment of brown-like or beige adipocytes2,6. Browning involves the expression of the transcriptional regulator PR 
domain containing 16 (PRDM16), which is involved in the expression of thermogenic molecules, such as the 
PPAR-γ coactivator (PGC1α) and uncoupling protein-1 (UCP-1)7.
BAT is predominantly found in the interscapular region of rodents, although it can also be present in perivas-
cular regions8. In adult humans, BAT is located in supraclavicular regions or around the neck9, and its discovery 
in humans emphasized the therapeutic potential of compounds that can alter energy expenditure and fuel metab-
olism in mammals, without the need for increasing physical activity, to address the global epidemics of obesity 
and diabetes10,11. Unlike white adipocytes, brown adipocytes store energy primarily to provide an intracellular 
source of fuel for thermogenesis9.
UCP-1 expression in adipocytes is the hallmark of BAT and is involved in the key step in thermogenesis, 
because it uncouples the mitochondrial respiratory chain, consequently generating heat (i.e., thermogenesis)10. 
Some known inducers of UCP-1 are cold exposure, food intake and the release of catecholamines5. These condi-
tions promote β-adrenergic receptor stimulation, increase the cAMP, activation of protein kinase A (PKA) and 
the consequent induction of PGC1α, which in turn induces PPARα and lipolysis, and ultimately induces the 
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expression of UCP-111. The importance of lipolysis is related to the finding that FFAs are the main fuels for ther-
mogenesis, and they also function as activators of UCP-112–14. Therefore, due to its high metabolic capacity, BAT 
is an attractive target for the treatment of obesity, diabetes, and other metabolic disorders14.
During the last years, our group has explored the potential therapeutic applications of a unique polypeptide 
isolated from the venom of the South American rattlesnake Crotalus durissus terrificus, known as crotamine15,16. 
Crotamine is a 42 amino acid residues long polypeptide with a high content of basic residues (approximately 25% 
of the residues are positively charged), with a well-defined tridimensional structure that distributes the positively 
charged side chains on the surface, thereby contributing to an amphipathic feature for this molecule17,18. As these 
characteristics are commonly found in cell penetrating peptides (CPPs)19, we also evaluated and demonstrated 
the cell penetrating property of crotamine20,21. Then, we described the ability of crotamine to penetrate eukary-
otic cells by endocytosis, in addition to functioning as a delivery vector and transporting therapeutic genes, and 
potentially also carrying other biologically active therapeutic molecules, with no detriment to its exceptional 
selectivity for actively proliferating cells20,22. These properties are important for the pleiotropic biological activities 
of crotamine, which include antimicrobial/antifungal22 and cytotoxic activities23, with a unique preference for 
highly proliferative cells, such as tumor cells22,24.
Despite the large spectrum of biological activities described to date for crotamine, knowledge about this poly-
peptide activity on healthy animal physiology remains very limited. Evidence that this toxin can act on metabolic 
pathways was first suggested by the observed decrease of body weight gain and increases in glucose tolerance 
when crotamine was orally administered daily to mouse models bearing subcutaneous melanoma tumors24. 
These effects of crotamine on body weight gain could potentially represent a limitation for using crotamine to 
treat cancer, as cachectic patients frequently experience unintended weight loss and episodes of hypoglycemia. 
Importantly, another group has demonstrated the ability of crotamine to induce insulin secretion in cultured 
pancreatic beta cells25. In the present study, the main objective was to investigate the metabolic effects of cro-
tamine in healthy wild-type mice after 21 days of oral treatment, which was demonstrated by our laboratory to 
be an effective protocol for crotamine as an antitumor treatment agent26. Here, we found that crotamine induces 
the differentiation of brown adipocytes and stimulates basal energy expenditure, thereby reducing adiposity and 
improving glucose homeostasis.
Results
Chronic treatment with crotamine by gavage reduces body weight gain. Mice treated for 21 days 
with crotamine (10 μg/animal/day) showed lower body weights compared to the control group that received only 
vehicle (Fig. 1a). Statistically significant differences in body weight gain of animals from crotamine-treated and 
control groups were first observed on the 14th day of treatment, and this difference remained significant until the 
last day of treatment (Fig. 1b). Decreased body weight gain was not due to differences in eating behavior, as no 
significant differences in food intake was observed between the crotamine-treated and untreated control groups 
(Fig. 1c). After euthanasia, the fat depots were removed from the animals and weighed. A significant increase 
Figure 1. Body weight gain, food intake rate, fat depot weights and fat index of animals after oral treatment. (a) 
Mean body weight (g), (b) body weight gain (g), (c) food intake (g), (d) weight of brown adipose tissue (BAT, 
g), (e) weight of subcutaneous white adipose tissue (WAT, g), (f) weight of the epididymal WAT (EAT, (g), and 
(g) fat index. The results are presented as the mean ± SEM of three independent experiments (in which cohorts 
were composed of 5 animals in each group). *p < 0.05 for comparison between the treated and untreated 
control groups.
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in BAT (Fig. 1d) and a significant reduction in subcutaneous WAT (Fig. 1e) and epididymal WAT depots were 
observed in crotamine-treated mice (Fig. 1f). In addition, the adiposity index (AI), which considers the sum of 
all isolated fat depots, was determined for both groups, showing significantly lower mean values for the group of 
animals treated daily with crotamine by oral gavage (Fig. 1g).
By contrast, this long-term treatment with crotamine did not significantly change the weights of liver, kid-
ney, heart or brain (Table 1). Additionally, no evidence of animal body growth retardation was observed after 
21 days of treatment with crotamine, as suggested by the absence of any significant differences in the weight of 
the skeletal muscles (gastrocnemius and soleus) or in the length of the bone (femur size) of the animals from the 
crotamine-treated or untreated groups (Table 1).
Crotamine treatment improves glucose tolerance and increases insulin sensitivity. A glucose 
tolerance test (GTT) demonstrated a clear improvement in glucose clearance after oral treatment with crotamine 
(Fig. 2a). The insulin tolerance test (ITT) showed increased insulin sensitivity in crotamine-treated animals 
(Fig. 2b).
Data obtained in the insulin tolerance test was also used to calculate the insulin-induced glucose decay rate 
(kITT), which is a bona fide marker of insulin action. Consistently, oral treatment with crotamine significantly 
increased the kITT (Fig. 2c).
Tissue (g) Control Crotamine
Liver 1.381 ± 0.061 1.351 ± 0.052
Kidney 0.192 ± 0.002 0.172 ± 0.002
Heart 0.188 ± 0.013 0.175 ± 0.004
Brain 0.262 ± 0.025 0.306 ± 0.013
Gastrocnemius 0.300 ± 0.001 0.300 ± 0.001
Soleus 0.020 ± 0.001 0.016 ± 0.002
Femur length (cm) 1.61 ± 0.04 1.60 ± 0.04
Table 1. Weight of the organs (liver, kidney, heart, and brain), skeletal muscle (gastrocnemius and soleus) and 
size (length) of the femur at the end of treatment with crotamine. Results are presented as the mean ± SEM of 
at least three independent experiments. *p < 0.05 for comparisons between the treated and untreated control 
groups.
Figure 2. Evaluation of glucose tolerance and insulin sensitivity. (a) Glucose tolerance test (GTT) and (b) 
insulin tolerance test (ITT), at 0, 5, 15, 30, 60 and 90 min after stimulus. The respective area under the curve 
(AUC) values for each curve are presented in the insets. (c) The constant rate of glucose disappearance 
calculated from (b), the glucose decay index (kITT). The results are presented as the mean ± SEM of seven 
independent experiments. *p < 0.05 for comparison between the treated and untreated control groups.
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Reduced lipid levels in plasma and tissue damage markers in mice treated with crotamine. 
Plasma was collected from mice soon after euthanasia, and parameters related to the metabolic status of the 
organism were measured. Significant reductions of triglycerides (Fig. 3a), total cholesterol (Fig. 3b), circulating 
low density lipoprotein (LDL) (Fig. 3c), and with only a trend towards increased high density lipoprotein (HDL) 
(Fig. 3d) levels were observed in crotamine-treated animals compared to the untreated control group receiving 
vehicle.
We also measured biomarkers of liver injury, and a trend towards a decrease of alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) levels was observed in the animals treated with crotamine (Figs 3e,f, 
respectively). Additionally, a significant decrease of gamma-glutamyl transpeptidase (gamma-GT) levels was 
observed in the plasma of crotamine-treated animals (Fig. 3g). Decreases in the levels of kidney injury biomark-
ers, i.e., creatinine (Fig. 3h) and uric acid (Fig. 3i), were also observed in the plasma of animals after 21 days of 
treatment with crotamine.
Basal energy expenditure. To assess the possible determinants for the reduced weight gain, we performed 
measurements in a Comprehensive Lab Animal Monitoring System (CLAMS), which allowed the evaluation of 
both the oxygen uptake (VO2) and carbon dioxide production (VCO2) in a period of 24 h divided into two cycles, 
in which the ‘light cycle’ corresponds to the period of low activity and the ‘dark cycle’ corresponds to the period 
of high metabolic and physical activities of mice27.
Increased energy expenditure denoted by increased heat production (HEAT) was noticed in the dark cycle 
compared to the light cycle, and the treatment with crotamine did not significantly affect this parameter (Fig. 4a). 
VO2 and VCO2 showed both a non-significant trend for higher values in the dark cycle compared to the light 
cycle, whereas no significant differences were observed for these parameters after treatment with crotamine 
(Fig. 4b,c).
Both groups consisting of animals treated with crotamine (experimental) or vehicle (negative control) pre-
sented respiratory exchange ratio (RER, which represents the substrate preference) values closer to 1 during the 
period of high metabolic activity (i.e., in the dark cycle) (Fig. 4d), which may suggest the preference for carbohy-
drates as an energy source. These values were significantly lower in the light cycle in both the experimental and 
negative control groups, and oral treatment with crotamine did not significantly influence RER values in either 
the dark or light cycles (Fig. 4d).
Ambulatory activity was also measured, and all animals (from both groups, i.e., crotamine-treated and 
untreated) showed higher locomotion in the dark cycle compared to the light cycle (Fig. 4e), as expected27. 
However, despite the increased energy expenditure, crotamine-treated animals showed a significant reduction 
in physical activity compared to the vehicle-treated control group (Fig. 4e). These data suggest that increased 
energy expenditure in crotamine-treated mice is likely due to an increase in the basal metabolic rate and/or heat 
production than altered physical activity.
Effect in vivo of crotamine on the expression of thermogenic markers in BAT. Thermogenic 
marker gene expression was analyzed and normalized to 18S using the total RNA extracted from the BAT of 
animals treated or not treated with crotamine. Treatment with crotamine by the oral route for 21 days showed a 
Figure 3. Biochemical evaluation of treated and untreated mice serum. (a) Triglycerides, (b) cholesterol, (c) 
LDL, (d) HDL, (e) ALT, (f) AST, (g) gamma-GT, (h) creatinine, and (i) uric acid. The results are presented as 
the mean ± SEM of six independent experiments. *p < 0.05 for comparison between the treated and untreated 
control groups.
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trend towards a reduced the expression of the beta-3 adrenergic receptor mRNA (Adrb3, Fig. 5a). By contrast, 
the expression of Pparα (Fig. 5b), Pgc1α (Fig. 5c) and Ucp-1 (Fig. 5d), which is the primary target for inducing 
thermogenesis in BAT, were all significantly increased in mice after treatment with crotamine for 21 days.
Crotamine effect on the in vivo recruitment of beige adipocytes in the subcutaneous WAT. To 
assess whether treatment with crotamine could induce beige adipocyte recruitment in WAT, two of the major 
markers of “browning”, i.e., Prdm16 and Ucp-128–30, were measured in subcutaneous WAT. Consistent with our 
hypothesis, a significant increase in the expression of beige adipocyte recruitment marker genes was observed in 
animals receiving crotamine by the oral route for 21 days (Fig. 5e–f).
In vitro differentiation and maturation of cultured brown preadipocytes in the presence of crotamine. 
The cell autonomous effects of crotamine on brown adipocytes was assessed using immortalized 9B brown pread-
ipocyte cultured cells, which were induced to differentiation in the presence of crotamine (5 μM), which was 
added at the first day of the differentiation process that lasted for 8 days. This resulted in a significant increase in 
the expression of Ucp-1 (Fig. 6a), Prdm16 (Fig. 6b) and Pgc1α (Fig. 6c). By contrast, a significant decrease in the 
expression of a pan-adipocyte marker Pparg was observed upon treatment with crotamine (Fig. 6d), suggesting 
that the effect of crotamine was not due to a general increase in the differentiation process. In addition, confocal 
imaging analysis of these immortalized brown preadipocyte cells (Fig. 7a–d) did show a significant increase in 
the number of lipid droplets per cell and mean size/diameter of the lipid droplets (Fig. 7e–f), when adipocyte cells 
were induced to differentiation in the presence of crotamine (5 μM).
Discussion
Natural products have significantly contributed to the discovery of several new compounds with potential as ther-
apeutics or as structural leads for the development of new drugs31. Some natural compounds, such as polyphenols 
and flavonoids, can reduce the absorption of lipids32 to induce lipolysis and subsequently decrease adiposity33. For 
example, green tea and caffeine were described to induce energy expenditure by increasing Ucp-1 expression in 
BAT34. However, natural compounds isolated from venomous animals have been less studied in this field, and an 
unexplored collection of molecules with potential to counteract obesity and ameliorate its complications remains 
Figure 4. Basal metabolic profile assessed by calorimetry of treated and untreated animals. (a) Energy 
expenditure (HEAT). (b) oxygen consumption (VO2), (c) carbon dioxide consumption (VCO2), (d) respiratory 
exchange ratio (RER), and (e) ambulatorial displacement. The results are presented as the mean ± SEM of two 
independent experiments (in which cohorts were composed of 4 animals in each group). Statistical analysis was 
performed using one-way ANOVA test with Bonferroni post hoc analysis to compare the quantitative results 
among samples from treated and untreated groups at light and dark cycles (#p < 0.05). Student T-test (*p < 0.05) 
was also used to show significant differences between the light and dark cycles.
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unexplored. Previous observations that crotamine inhibits weight gain in animal models of melanoma24,26 led us 
to explore the potential effects of crotamine on metabolism.
Here, we demonstrate that crotamine stimulates brown/beige adipocyte differentiation/activation both in vivo 
and in vitro. In B16F10 and CHO-K1 cells, crotamine was shown to promote Ca2+ release from intracellular 
stores21,35. Interestingly, increases in intracellular free Ca2+ activates calcineurin and inhibits ERK phosphoryla-
tion, which in turn inhibits brown adipocyte differentiation36,37. By contrast, we show that crotamine promotes 
activation of BAT function and differentiation, suggesting that this polypeptide does not act through calcineurin 
and ERK. However, more experiments are required to test the mechanism by which crotamine acts directly in 
preadipocytes to promote brown adipocyte differentiation. Moreover, the mechanisms of action of crotamine in 
eukaryotic cells at sub-lethal concentrations remain largely unexplored.
In vivo, the direct effect of crotamine on browning is likely potentiated by other systemic, indirect actions. In 
the present work, expression of the β3 adrenergic receptor mRNA was decreased in BAT upon the treatment of 
mice with crotamine for 21 days by the oral route. We hypothesize that the adrenergic tonus of crotamine-treated 
mice could be increased, sustaining thermogenic activity and promoting BAT expansion, in which a given recep-
tor expression is decreased in response to the high levels of its ligand38–40.
Interestingly, crotamine may also play a role in glucose tolerance by affecting insulin release, as crotamine 
affects K+ channels and intracellular Ca2+ pool dynamics21,41,42 and controls the secretion of insulin-containing 
intracellular vesicles25,43.
In this study, the ability of the polypeptide crotamine to act in BAT and WAT of mice to inhibit body weight 
gain and to stimulate a pro-thermogenic profile that favors energy expenditure was shown. Therefore, we propose 
a direct effect of crotamine in brown preadipocytes, in addition to possible systemic effects in vivo. By inducing 
browning, crotamine leads to reduced body weight gain, which in turn favors insulin sensitivity. Brown/beige 
Figure 5. Evaluation of thermogenic marker expression in BAT and WAT of treated and untreated animals. 
Gene expression of (a) β-3 adrenergic receptor (Adrb3), (b) Pparα, (c) Pgc1α, and (d) Ucp1 in BAT, and gene 
expression of transcription factor (e) Prdm16 and (f) Ucp1 in WAT, all normalized against 18S. Data are the 
mean ± SEM of three independent experiments. *p < 0.05 for comparison between the treated and untreated 
control groups.
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adipocytes also consume high amounts of glucose and lipids, which explains the improved glucose tolerance 
and reduced triglyceride levels, respectively, in animals treated with crotamine. BAT plays a fundamental role in 
maintaining body temperature by producing heat, and crotamine effects on the metabolism of wild type healthy 
mice (without tumor) inducing browning as shown in the present study precludes any possible cachexia-like 
effect of this polypeptide.
Cancer cachexia is a paraneoplastic syndrome characterized by body weight loss, muscle wasting, adipose 
tissue atrophy and inflammation44, in which muscle wasting has emerged as a principal component of cancer 
cachexia, leading to progressive impairment of work capacity45. Here, we showed that despite the significant 
decrease of body weight gain after oral treatment with crotamine, no significant body weight loss or decrease in 
skeletal muscle, brain, kidney or heart weight was observed. In addition, the size of the femur bone of animals 
was also the same regardless of treatment with crotamine. In addition to the loss of body weight, most advanced 
cancer patients frequently suffer loss of appetite (anorexia), which contributes to cachexia, whereas mice treated 
with crotamine only have decreased body weight gain but with no significant change in food intake. Additionally, 
analysis of biochemical biomarkers for liver and kidney dysfunction showed a trend towards decreased levels after 
treatment with crotamine, suggesting no potential damage to liver or kidney functions. Interestingly, antioxidants 
that protect and improve mitochondrial respiration reduced these biochemical biomarkers of organ dysfunction, 
including ALT and creatinine46, and crotamine action on mitochondria was also previously suggested by us21.
Taken together, our data open new roads for the exploration of novel pharmacological leads based on cro-
tamine structure to treat obesity or dysfunctions associated with weight gain and insulin resistance. However, fur-
ther studies are necessary to demonstrate the efficacy of crotamine in animal models of diseases, such as obesity 
or diabetes. Similarly, the mechanism(s) underlying these effects must be better elucidated by us at the molecular 
level, with the main focus on the direct action of crotamine direct on preadipocytes to identify possible molecular 
targets or pathways with therapeutic value.
Materials and Methods
Purification of crotamine. The venom of Crotalus durissus terrificus was extracted from rattlesnakes kept 
captive at the Ribeirão Preto Medical School (FMRP) Serpentarium of University of São Paulo (USP), and native 
crotamine was purified according to the previously described protocol47.
Animals. Male C57BL/6 mice, 12 weeks old, obtained from the Animal Experimentation Laboratory of 
INFAR at the Federal University of São Paulo (UNIFESP/EPM - SP, Brazil) were divided in 2 experimental 
groups: the control sham group, treated with vehicle (n = 8), and the experimental group, treated with crotamine 
(n = 8). The animals were maintained under controlled temperature (19 °C), light/dark cycle every 12 h, and they 
Figure 6. Evaluation of expression of markers for differentiation and activation of brown adipocytes (9B). Gene 
expression of the transcription factors (a) Prdm16 and (b) Pparγ, (c) Pgc1α, and (d) Ucp1 normalized against 
18S is shown, and the results are presented as the mean ± SEM of five independent experiments. *p < 0.05 for 
comparison between the treated and untreated control groups.
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were supplied with water and food ad libitum. All procedures with the animals were in accordance with the stand-
ards described in the Guidelines for Ethical Conduct in the Care and use of Animals, the American Psychological 
Association* and the Guideline of the Committee on Care and Use of Laboratory Animal Resources of the 
National Research Council of the United States of America. The Research Ethics Committee of UNIFESP 
approved all procedures performed in this study (CEUA No. 1361030315).
Treatment of animals. The animals from the treated group received 10 µg of crotamine in 100 µL of filtered 
water daily through an orogastric tube (gavage). The control group also received 100 μL of filtered water by oral 
administration. The treatment lasted for 21 days, as adopted previously for antitumor treatment24.
Body weight gain and food intake evaluation. During the experimental period, the animals were 
weighed weekly using a semi-analytical balance. The dietary intake was calculated weekly as the difference of the 
initial quantity supplied and the remaining amount of food (in grams).
Insulin Tolerance Test (ITT). First, a sample of blood (1 drop of approximately 10 µL) was collected from 
the animals fasted for 8 h after making a small cut (of approximately 3 mm) at the extremity of the animal tail, at 
time zero of the experimental procedure. After the first collection (time zero), regular insulin (0.5 U/kg, Biobrás, 
Figure 7. Confocal imaging of differentiated adipocyte cells. Immortalized brown preadipocytes were induced 
to adipocyte differentiation in the absence (a and b) or presence (c and d) of crotamine (5 μM). Differential 
interference contrast (DIC) imaging (a and c) allows the morphological visualization of cells and of lipid 
vesicles, whereas the nucleus of the cells and lipid vesicles are shown by DAPI (λEx 405 nm/λEm 420–470 nm) 
and red O oil (λEx 543 nm/λEm 555–625 nm) staining, respectively (b and d). Scale bars = 10 μm. The average 
number of lipid droplets per cell (e) and the mean value of diameter of lipid droplets (f) were determined by 
using ImageJ software (N = 50 cells). *p < 0.05 for comparison between the treated and untreated control 
groups.
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São Paulo, Brazil) was injected, and blood samples were collected after 5, 10, 15, 30, 60 and 90 min for glucose 
measurements using the Accu-check blood glucose meter (Roche Diagnostics, Mannheim, Germany).
Glucose tolerance test (GTT). Two days after the ITT test, a sample of blood (1 drop approximately 10 µL) 
was collected from each animal fasted for 8 h through a new cut of approximately 3 mm at the extremity of the 
animal tail, to determine the glucose concentration in the blood at time 0 (or namely, ‘background level’ for the 
fasted animal). Then, a glucose solution was administered by intraperitoneal (IP) injection in a dose of 1 g of glu-
cose/kg of animal body weight. Blood samples from each animal were collected again from the same tail cut at 5, 
10, 15, 30, 60 and 90 min after glucose injection for the measurement of blood glucose levels using an Accu-check 
blood glucose meter system (Roche Diagnostics). The obtained values were also used for construction of the 
tolerance curve.
Biochemical analysis of the plasma. The total volume of blood collected from each animal (~ 0.5 mL) 
was placed in single microtube containing EDTA that was centrifuged for 10 min at 300 × g at room temperature 
for plasma fraction (supernatant) collection. Aliquots of plasma were stored in 0.2 mL microtubes at −80 °C until 
analysis. Specific kits, all from BIOCLIN (São Paulo, Brazil) were used to determine the plasma concentration 
of triglycerides (Triglicerides Monoreagente – K117), total cholesterol (Colesterol Monoreagente – K083), uric 
acid (Ácido Úrico Monoreagente – K139), creatine (Creatinina Enzimática – K161), alanine aminotransferase 
(ALT, Transaminase ALT (TGP) Cinética – K049), aspartate aminotransferase (AST, Transaminase AST (TGO) 
Cinética – K048) and gamma-glutamyl transpeptidase (gamma-GT, Gama GT Cinético – K080), which were used 
according to the manufacturer’s instructions.
Basal metabolic rate. The basal metabolic rate of each animal was assessed 14 days after experimentation 
using an indirect open circuit calorimeter Oximax model (Columbus Instruments, Ohio, USA). First, the animals 
were acclimated for 24 h in cages (one animal/cage) under 12 h light/dark cycle with food and water ad libitum, 
and they were kept under these conditions for the experimental period, which lasted for over 24 h. The animals 
were subjected to non-invasive monitoring of gas exchange and physical activity. The rates of oxygen consump-
tion (VO2) and CO2 production (VCO2), as well as respiratory exchange ratio (RER), were determined following 
the manufacturer’s instructions. Animal displacement was measured using light sensors installed at the base of 
the cages.
Tissue collection and adiposity index evaluation. Immediately after euthanasia, a midline laparotomy 
was performed in each animal for the extraction of white adipose tissues (epididymal, perirenal and subcutane-
ous), brown adipose tissue (BAT), kidney, heart, brain, liver, and gastrocnemius and soleo skeletal muscles. The 
tissues and organs were individually weighed using an analytical balance. The sum of the fat tissue weight was 
normalized by the average body weight of the respective group to determine the adiposity index (AI), using the 
Equation (1) below.
= + +AI WAT WAT BAT/mean body weight (1)sub epi
Brown preadipocyte cell culture and confocal microscopy. The brown preadipocyte cell line 9B are 
immortalized dicerfl/fl brown preadipocytes48. These cells were isolated from the intrascapular brown adipose 
tissue of newborn dicerfl/fl mice upon collagenase digestion (1.5 mg/mL; Worthington Biochemical, Lakewood, 
NJ, USA). After two days in culture, the cells were immortalized using retrovirus harboring the pBabe SV40 
Large T antigen puromycin vector. Dicerfl/fl mice behave similar to wild type mice as do the cells, which express 
a high levels of UCP1 and are highly uncoupled (unpublished data). These cells were grown and expanded with 
DMEM medium (Sigma Aldrich, St. Louis, USA) and supplemented with 10% fetal bovine serum (FBS). Then, 
the cells were cultured at 37 °C with 5% CO2, and treated with a cocktail of drugs for differentiation (insulin, 
dexamethasone, rosiglitazone, IBMX (3-isobutyl-1-methylxanthine), indomethacin, T3 and isoproterenol) for 8 
days in the presence of crotamine (5 μM) that was replaced every 2 days with cells washing and medium changes 
(as schematically demonstrated in Fig. 8).
After the differentiation process, the cells were collected and stored at −80 °C until use or they were cultured 
on cover glasses mounted with anti-fading medium containing DAPI for imaging analysis by confocal micros-
copy in a Leica TCS SP8 confocal microscope (Leica Microsystem, Wetzlar, Germany) using an oil immersion 
objective of 63× (as detailed in the figure legend), at wavelengths λEx 405 nm/λEm 420–470 nm for DAPI fluores-
cence. Lipid accumulation was visualized at day 8 of differentiation by red O oil staining (Aldrich Sigma). Cells 
were washed once with PBS and were fixed by immersion in PBS + 10% formaldehyde for 15 min, at 4 °C. Cells 
were then stained with filtered red O oil solution (5 g/L in isopropyl alcohol) diluted 2-fold in water. After incuba-
tion for 1 h at room temperature, the cells were rinsed several times with distilled water to remove the excess stain 
and precipitates. For imaging analysis by confocal microscopy on a Leica TCS SP8 confocal microscope (Leica 
Microsystem), red O oil were detected at wavelengths of λEx 543 nm/λEm 555–625 nm. For the measurement of 
the apparent lipid droplet diameter and determination of number of lipid droplets per cell, micrographs obtained 
by confocal microscopy were analyzed using ImageJ software49.
Quantitative RT-PCR. The mRNA was extracted from the BAT and WAT samples using Trizol® reagent. 
Then, the cDNA was synthesized using the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen 
by Life Technologies, Carlsbad, California, USA). The gene expression rate was then evaluated by quantitative 
real-time PCR (qPCR), and each reaction mixture containing 250 nM of each primer (sense and antisense), 25 
ng of cDNA and 1 × Maxima SYBR-Green Master Mix in a final volume of 10 μL was analyzed in a Stratagene 
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Mx 3000 P qPCR system (Thermo Fisher Scientific, Waltham, MA, USA) under the following amplification con-
ditions: 50 °C-2 min, 95 °C-10 min, 40 cycles of 95 °C-15 s, 60 °C-20 s and 72 °C-30 s. Dissociation protocols were 
used to evaluate the efficacy of the primers for specifically amplifying the target genes. The sequence of the prim-
ers for the genes of interest and a housekeeping gene (18S) as the endogenous control used in our experiments 
are shown in Table 2. The threshold cycle (CT) values derived from the real-time PCR assay for each gene were 
divided by the CT values of the internal control 18S, and these ratio values were used to prepare the graphics.
Analysis of data. The results presented here are expressed as the mean ± standard error of the mean (SEM). 
Statistical analysis was performed using two-way ANOVA test with Bonferroni post hoc analysis to compare the 
quantitative results among multiple samples. Statistical differences between two means were determined by the 
Student “t” test. The significance level to reject the null hypothesis was set at 5% (p < 0.05).
Data availability statement. The datasets generated during and/or analyzed during the current study are 
available from the corresponding author upon reasonable request.
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